Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence

Scuteri, Damiana; Rombolà, Laura; Hamamura, Keisuke; Sakurada, Tsukasa; Watanabe, Chizuko; Sakurada, Shinobu; Guida, Francesca; Boccella, Serena; Maione, Sabatino; Afflitto, Gabriele Gallo; Nucci, Carlo Alberto; Tonin, Paolo; Bagetta, Giacinto; Corasaniti, Maria Tiziana

doi:10.1016/j.biopha.2021.112505

Cited by 7 publications

(5 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latter observation supports evidence of having BEO anxiolytic-like effects, and that limonene plays an important role since high locomotory activity is associated with attempts to escape, resulting in being a remarkable behavioral indicator of anxiety [18]. Incidentally, these effects have been demonstrated to be devoid of the sedation that is typical of benzodiazepines [19] and to involve serotonergic neurotransmission [20] that is separate from the possible role of the glutamatergic and endocannabinoid systems [21][22][23]. This is fundamental since the glutamatergic [24,25] and serotonergic [26] mechanisms are significantly involved in aging and neurodegeneration and, thus, they are also involved in the mechanism of action of rapid acting antidepressants [27].…”

Section: Discussionmentioning

confidence: 56%

Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy

et al. 2022

View full text Add to dashboard Cite

Bergamot essential oil (BEO) is endowed with consistent and reproducible antinociceptive and anti-allodynic properties when administered via an inhalation route. However, the effects of its main constituents and of its decolored (DEC) and deterpenated (DET) fractions, which are enriched in limonene or in linalool and linalyl acetate, respectively, on spontaneous motor activity related to anxiety and on formalin-induced licking/biting biphasic behavior have never been investigated before. Therefore, the present research aims to characterize the role of BEO components on an experimental pain model that is relevant to clinical translation. Under our present experimental conditions, a paper filter disc soaked with different volumes of the phytocomplex and of its fractions that was applied at the edge of the observation chamber allowed the effects on the spontaneous motor activity and on the formalin-induced nocifensive response in ddY-strain mice to be studied. The present research demonstrated the effects of the DEC fraction of BEO on motor activity and on formalin-induced licking/biting behavior for the first time, proving that limonene is implicated in reduced motor activity and that it is important for the analgesic effect.

show abstract

Section: Discussionmentioning

confidence: 56%

Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…They comprise a class of endogenous cannabinoids, a group of arachidonic acid derivatives such as anandamide (Skaper et al., 2013; Thomas et al., 2020). These endogenous analgesic compounds are expressed and released during injury by hydrolysis of phospho‐lipid molecules in cell membranes and they are agonists for CB1 and CB2 cannabinoid receptors (Scuteri et al., 2022; Thomas et al., 2020; Yang et al., 2013). While tetrahydrocannabinol is considered to be a nonselective CB1 and CB2 agonist, it can activate other receptors, including the serotonin 1A receptor (5‐HT 1A ), to ameliorate neuropathic pain (Donvito et al., 2018; Thayer et al., 2020).…”

Section: Mechanisms Involved In the Pathophysiology Of Neuropathic Painmentioning

confidence: 99%

Neurophysiology of corneal neuropathic pain and emerging pharmacotherapeutics

Asiedu

2023

J of Neuroscience Research

View full text Add to dashboard Cite

The altered activity generated by corneal neuronal injury can result in morphological and physiological changes in the architecture of synaptic connections in the nervous system. These changes can alter the sensitivity of neurons (both second‐order and higher‐order projection) projecting pain signals. A complex process involving different cell types, molecules, nerves, dendritic cells, neurokines, neuropeptides, and axon guidance molecules causes a high level of sensory rearrangement, which is germane to all the phases in the pathomechanism of corneal neuropathic pain. Immune cells migrating to the region of nerve injury assist in pain generation by secreting neurokines that ensure nerve depolarization. Furthermore, excitability in the central pain pathway is perpetuated by local activation of microglia in the trigeminal ganglion and alterations of the descending inhibitory modulation for corneal pain arriving from central nervous system. Corneal neuropathic pain may be facilitated by dysfunctional structures in the central somatosensory nervous system due to a lesion, altered synaptogenesis, or genetic abnormality. Understanding these important pathways will provide novel therapeutic insight.

show abstract

“…Its adverse effects include liver toxicity, somnolence, decreased appetite, diarrhea, and low blood pressure [ 3 ]. In addition, Scuteri et al, a systematic review of four studies, revealed that CB2 agonist HU308 alleviates inflammation in the eyes by reducing uveitis-induced leukocyte adhesion and lipidome profile changes [ 20 ]. It also highlights the antinociceptive and anti-inflammatory effects of D8-THC, cannabidiol, derivative HU308, and the new racemic CB1 allosteric ligand [ 20 ].…”

Section: Reviewmentioning

confidence: 99%

“…In addition, Scuteri et al, a systematic review of four studies, revealed that CB2 agonist HU308 alleviates inflammation in the eyes by reducing uveitis-induced leukocyte adhesion and lipidome profile changes [ 20 ]. It also highlights the antinociceptive and anti-inflammatory effects of D8-THC, cannabidiol, derivative HU308, and the new racemic CB1 allosteric ligand [ 20 ]. Another study with 2224 patients by Maurer et al revealed that the patients’ post-injury three and four-week use of cannabis after concussions resulted in a lower severity score but not faster recovery from concussion symptoms [ 5 ].…”

Section: Reviewmentioning

confidence: 99%

Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review

Villanueva¹,

Joshaghani²,

Villa³

et al. 2022

Cureus

View full text Add to dashboard Cite

We conducted a systematic review to determine the efficacy and safety of cannabidiol (CBD) for chronic pain. The systematic review is according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 checklist. Five databases (PubMed, PubMed Central, Medline, Cochrane Library, and ScienceDirect) were searched using cannabidiol, CBD, hemp, and chronic pain. Inclusion criteria used were studies on adult populations >18 years old; pain symptoms >three months duration; all available preparations of CBD; human studies only; publication in English in the past five years. A total of 2298 articles were found. Inclusion criteria were applied, and quality assessments were done, resulting in 12 publications eligible for the review. CBD and tetrahydrocannabinol (THC), both from Cannabis plants with almost identical chemical structures, attach to the CB receptor, eliciting different effects like the psychoactivity seen on THC but less or none in CBD. Regulations of CBD worldwide differ from each other due to the insufficiency of solid evidence to establish its benefit versus the risks. However, a few studies are showing the benefits of CBD not only for chronic pain but also for sleep improvement and quality of life. In conclusion, CBD is an excellent alternative to an opioid in chronic pain because CBD is non-intoxicating in its pure form. More clinical trials should be done to prove CBD's significance clinically and statistically.

show abstract

Is there a rational basis for cannabinoids research and development in ocular pain therapy? A systematic review of preclinical evidence

Cited by 7 publications

References 68 publications

Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy

Preclinical Characterization of Antinociceptive Effect of Bergamot Essential Oil and of Its Fractions for Rational Translation in Complementary Therapy

Neurophysiology of corneal neuropathic pain and emerging pharmacotherapeutics

Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review

Contact Info

Product

Resources

About